(Q34636988)

3 August 2017

1 reference

title

Inhibitors: resolving diagnostic and therapeutic dilemmas (English)

1 reference

3 August 2017

Dimichele D

1

1 reference

3 August 2017

publication date

1 May 2002

1 reference

3 August 2017

1 reference

3 August 2017

volume

8

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

280-287

1 reference

Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00626.X

Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00626.X

Haemophilia B mutations in Sweden: a population-based study of mutational heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00626.X

Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00626.X

Epidemiology of inhibitor development in haemophilia A patients treated with virus-inactivated plasma-derived clotting factor concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00626.X

Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00626.X

Factor VIII inhibitors in mild and moderate-severity haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00626.X

Factor IX inhibitors and anaphylaxis in hemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00626.X

The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00626.X

Malmö International Brother Study (MIBS): an international survey of brother pairs with haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00626.X

Factor VIII and factor IX inhibitors in haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00626.X

Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00626.X

The French haemophilia cohort: rationale and organization of a long-term national pharmacosurveillance system

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00626.X

Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00626.X

Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00626.X

The effect of protein kinase C activation on G(z)-mediated regulation of type 2 and 6 adenylyl cyclases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00626.X

Continuous infusion of porcine factor VIII in patients with haemophilia A and high-responding inhibitors: stability and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00626.X

Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00626.X

Immunoadsorption for removal of inhibitors: update on treatments in Malmö-Lund between 1980 and 1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00626.X

International immune tolerance registry, 1997 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00626.X

The German National Immune Tolerance Registry, 1997 update. Study Group of German Haemophilia Centres

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00626.X

Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00626.X

Factor IX antibody and immune tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00626.X

Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00626.X

10.1046/J.1365-2516.2002.00626.X

21 January 2018

Identifiers

DOI

1 reference

release_kaythqcervdb3j3mogonk7cuna

3 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kaythqcervdb3j3mogonk7cuna

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference